Latest News & Features
Americas
Researchers should keep in mind that broad claims applying the discovery of a biomarker and disease correlation are currently patentable in Europe but not in the US. Andrew Carridge and Neil Thornton of Reddie & Grose report. 17 September 2015
Americas
Many players are piling into the scrum surrounding the patent eligibility of CRISPR technology. Mercedes Meyer of Drinker Biddle & Reath discusses the legal implications of CRISPR as a potential groundbreaking foundation technology. 17 September 2015
Big Pharma
Aldgate Tower will make an ideal home for the UK division of the UPC, with many advantages for its likely users, says Claire Phipps-Jones of Bristows. 10 September 2015
Americas
Congress has apparently taken note of the strategy of hedge fund manager Kyle Bass to take advantage of the IPR process, with two pending patent reform bills which include provisions that could curtail his activities, says John Abramic of Steptoe & Johnson. 3 September 2015
Big Pharma
The competence in various areas of the new Unified Patent Court is a matter of conjecture, as Paul England and Christof Höhne of law firm Taylor Wessing report. 27 August 2015
Americas
A recent decision in Canada means defendants in patent infringement cases can raise the non-infringing alternative defence in response to damages claims. Mark Biernacki and Cameron Weir of Smart & Biggar/Fetherstonhaugh considers its potential impact on litigation between drugs companies. 20 August 2015
article
US Congress must exempt biopharmaceutical patents from PTAB review to ensure continued medical innovation, argues Peter Pitts of the Center for Medicine in the Public Interest. 13 August 2015
Europe
Proactively managing patent portfolios is an investment that pays for itself in reduced patent costs. Bruno Reynolds, who works at the consultancy arm of Isis Innovation, the technology transfer company of the University of Oxford, explains more. 6 August 2015
Americas
On July 21 the US Court of Appeals for the Federal Circuit ruled in Amgen v Sandoz that biosimilar applicants can opt out of the ‘patent dance’. Courtenay Brinckerhoff of Foley & Lardner considers the decision’s implications for the biosimilars framework and highlights the questions that remain unanswered. 30 July 2015
Americas
Biopharma parties thinking about challenging a patent via an inter partes review should be aware that there are significant differences between district court and IPR practice, as Tasha Francis and Dorothy Whelan of Fish & Richardson explain. 23 July 2015